209 related articles for article (PubMed ID: 9291242)
1. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Tcheng JE
Am J Cardiol; 1997 Aug; 80(4A):21B-28B. PubMed ID: 9291242
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of eptifibatide.
Phillips DR; Scarborough RM
Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
[TBL] [Abstract][Full Text] [Related]
3. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
4. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Harrington RA
Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244
[TBL] [Abstract][Full Text] [Related]
5. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Kleiman NS
Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243
[TBL] [Abstract][Full Text] [Related]
6. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
Zeymer U
Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng JE
Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
Granada JF; Kleiman NS
Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
[TBL] [Abstract][Full Text] [Related]
9. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Berkowitz SD
Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
[TBL] [Abstract][Full Text] [Related]
10. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa.
Lorenz TJ; Macdonald F; Kitt MM
Clin Ther; 1999 Jan; 21(1):128-37. PubMed ID: 10090430
[TBL] [Abstract][Full Text] [Related]
11. Development of eptifibatide.
Scarborough RM
Am Heart J; 1999 Dec; 138(6 Pt 1):1093-104. PubMed ID: 10577440
[TBL] [Abstract][Full Text] [Related]
12. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
Fernandes LS; Tcheng JE; O'Shea JC; Weiner B; Lorenz TJ; Pacchiana C; Berdan LG; Maresh KJ; Joseph D; Madan M; Mann T; Kilaru R; Hochman JS; Kleiman NS;
J Am Coll Cardiol; 2002 Sep; 40(6):1085-91. PubMed ID: 12354432
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
[TBL] [Abstract][Full Text] [Related]
14. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Curran MP; Keating GM
BioDrugs; 2006; 20(1):63-5. PubMed ID: 16573353
[TBL] [Abstract][Full Text] [Related]
16. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
Chong PH
Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
[TBL] [Abstract][Full Text] [Related]
18. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
[TBL] [Abstract][Full Text] [Related]
19. Eptifibatide in percutaneous coronary intervention. A review.
Dery JP; O'Shea JC; Tcheng JE
Minerva Cardioangiol; 2002 Oct; 50(5):531-46. PubMed ID: 12384635
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review.
Truong KM; Amankwa K; Kucukarslan S
Clin Ther; 2001 Aug; 23(8):1145-65; discussion 1129. PubMed ID: 11558855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
